Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EORTC Groups Annual Meeting (EGAM) 2019 /
Breast cancer trials and the ageing population

14th - 15th Mar 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.03.19
Views: 831

Dr Etienne Brain - Institut Curie, Paris, France

Dr Etienne Brain speaks to ecancer at the 2019 EORTC Groups Annual Meeting (EGAM) about the recent trial developments from the EORTC Breast Cancer Group - which he currently chairs.

Dr Brain describes a new randomised trial called 'Appalaches' that will examine the adjuvant administration of palbociclib in older ER-positive, HER2-negative patients.

He also discusses the clinical implications that may result from these studies, in which he believes clinical research must become more considerate of the current ageing population.

Dr Brain also mentions further trials that are in development that will focus on the de-escalation of aggressive treatments in both the ageing and general population.

Furthermore, Dr Brain outlines the main challenges faced in oncology today, along with hopes to address the disparity between young and older patients in clinical trials.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation